Please assess the completion status of the following clinical trial:

Trial Title: Safety of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Erectile Dysfunction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Postprostatectomy Erectile Dysfunction~* A man aged 20 or older~* Who is willing to consent to participate in the study concerned with improving sexual activity after prostatectomy, the man has maintained normal sexual activity prior to prostatectomy~* Prior to prostatectomy PSA (prostate specific antigen) level\<10 ng/mL~* At the time of Prostatectomy, Pathological Gleason sum ≤7~* At the time of Prostatectomy, Pathological stage ≤ T2c~* 2 years or more postprostatectomy patients with PSA level ≤ 0.04 ng/mL without additional therapy after prostatectomy~* Who cannot satisfy sexual activity(more than 4 times) with proper sexual stimulation in spite of taking maximum dose of oral PDE5I(phos-phodiesterasetype-5 inhibitors) within last 8weeks.~* IIEF, EF(erectile function) domain score is under 17~* Have a consistent partner who is willing to engage in sexual activity more than twice per month during the study.~Diabetes-associated Erectile Dysfunction~* HbA1c is between 6.5% and 10% of man over 20 years of age with diabetes~* Who cannot satisfy sexual activity(more than 4 times) with proper sexual stimulation in spite of taking maximum dose of oral PDE5I within last 8weeks.~* IIEF, EF domain score is under 17~* Who is willing to consent to participate in the study concerned with improving sexual activity~* Have a consistent partner who is willing to engage in sexual activity more than twice per month during the study.~Exclusion Criteria:~* History of bone marrow disorders~* Serum AST/ALT \> 3 X upper limit of normal or Creatinine \> 1.5 X upper limit of normal~* History of hypersensitivity against a gentamycin~* Severe cardiovascular disease(angina, arrhythmia, cardiac failure, stroke), kidney failure, respiratory failure~* Positive for human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) and syphilis test~* Positive for PSA or CEA or AFP (Carcinoembryonic antigen), history of cancer in the last five years (except Prostatic cancer) Uncontrolled hypertension or hypotension (systolic blood pressure \> 170 or \< 90 mm Hg, diastolic pressure \> 100 or \< 50 mm Hg)~* HbA1c exhibit greater than 10%~* Men on anticoagulant treatment~* Have a severe infectious disease~* Testosterone level is less than 200ng/dl~* Have a penile implant or willing to it~* Patients with morphological changes of the penis~* Patient's partner is trying to conceive during the trial period~* Unwilling to participate in the study~* Participating in other clinical trials in the past 30 days~* Unable to compliance with protocol~* Inappropriate patients to participate in the study according to the investigator

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mesenchymal stem cell (Type: EXPERIMENTAL): Patients will receive single intracavernous injection of Mesenchymal stem cell. Oral PDE5-inhibitor can take on demand.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete